BRAF and colorectal carcinoma: Results from our analysis suggest the presence of adaptive mutability in a cohort of patients with BRAF-V600E CRC treated with BRAF inhibitor in combination with an anti-EGFR monoclonal antibody, with or without a MEK inhibitor.